Literature DB >> 2771073

Clozapine in the treatment of psychosis in Parkinson's disease.

J H Friedman1, M C Lannon.   

Abstract

Clozapine is an antipsychotic medication that is virtually free of extrapyramidal side effects. We report our successful treatment of 6 patients with idiopathic Parkinson's disease and various psychoses using clozapine on a chronic basis along with carbidopa/L-dopa.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2771073     DOI： 10.1212/wnl.39.9.1219

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  14 in total

Review 1.  Pharmacological treatment of Parkinson's disease.

Authors:  A Münchau; K P Bhatia
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

Review 2.  New atypical antipsychotics. Experience and utility in the elderly.

Authors:  R A Sweet; B G Pollock
Journal:  Drugs Aging       Date:  1998-02       Impact factor: 3.923

3.  New therapeutic strategies targeting D1-type dopamine receptors for neuropsychiatric disease.

Authors:  Young-Cho Kim; Stephanie L Alberico; Eric Emmons; Nandakumar S Narayanan
Journal:  Front Biol (Beijing)       Date:  2015-05-13

Review 4.  Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.

Authors:  B K Young; R Camicioli; L Ganzini
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

Review 5.  Parkinson's disease.

Authors:  C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-06       Impact factor: 10.154

Review 6.  Diagnosis and treatment of Parkinson's disease in the elderly.

Authors:  J I Sage; M H Mark
Journal:  J Gen Intern Med       Date:  1994-10       Impact factor: 5.128

Review 7.  Drug treatment of Parkinson's disease.

Authors:  N Quinn
Journal:  BMJ       Date:  1995-03-04

Review 8.  A risk-benefit assessment of drugs used in the management of Parkinson's disease.

Authors:  I Y Bodagh; D R Robertson
Journal:  Drug Saf       Date:  1994-08       Impact factor: 5.606

Review 9.  Current status of dopamine agonists in Parkinson's disease management.

Authors:  J L Montastruc; O Rascol; J M Senard
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

Review 10.  The serotonergic system in motor and non-motor manifestations of Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox
Journal:  Exp Brain Res       Date:  2013-06-28       Impact factor: 1.972
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.